🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Galectin Therapeutics Inc. GALT PHARMA

Healthcare · Biotechnology · United States
https://galectintherapeutics.com
Company Profile ↓
$4.14
+12.81% 1Y
Mkt Cap$417.52M
P/E-9.63
P/B-1.86
52W High$6.51
52W Low$2.08
Book Value$-2.10
EPS (TTM)$-0.43

Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 24.1%, reflecting efficient use of shareholder capital.

Growth & Price Performance

Stock Price Performance

1 Year:+12.81%
6 Months:+23.58%
3 Months:+72.50%
1 Month:+20.00%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 47% of range
$2.08 $6.51
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)55.29 · Neutral
Price Performance
1M+20.00%
3M+72.50%
6M+23.58%
1Y+12.81%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 24.1%.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 36.4% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-9.63
Industry PE
24.83
Forward P/E
-2.46
PEG Ratio
-36.15
Book Value
$-2.10
Price to Book
-1.86
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
24.11%
ROA
-64.18%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.08
EPS (TTM)
$-0.43

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
0.09
Current Ratio
0.10
Debt
$143.96M
Total Assets
$15.76M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
53.08%
Chg in Prom Hold
23.99%
FII / Inst Holding
15.66%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
$417.52M
Total Revenue (TTM)
-
EBITDA
-
Free Cash Flow
$-14.86M
Operating Cash Flow
$-15.89M
Shares Outstanding
100.85M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GALT Galectin Therapeutics Inc. PHARMA 4.14 -9.63 $417.52M 0.00% - 24.11% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2013Mar 2014Jun 2014Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Operating Income --4.84M-3.38M-3.48M--4.84M-4.66M-5.90M--6.81M-5.53M-4.54M-4.95M-4.51M-4.41M-4.18M-3.76M-2.68M-2.37M-3.02M-2.86M-3.58M-6.10M-5.93M-6.32M-8.19M-8.24M-9.94M-9.66M-8.12M-10.34M-9.00M-9.17M-9.65M-11.29M-9.07M-7.90M-4.62M-4.20M-4.08M
Net Income -2.80M-5.11M-3.43M-3.52M-3.73M-4.83M-4.64M-5.89M-4.67M-6.80M-5.52M-4.53M-4.94M-4.51M-4.41M-4.26M-3.84M-2.75M-2.38M-3.00M-2.78M-3.56M-6.11M-5.94M-6.34M-8.45M-8.52M-9.93M-9.61M-8.60M-11.53M-9.11M-10.43M-11.49M-12.37M-11.22M-9.63M-7.52M-8.18M-5.05M
Diluted EPS ------------------------0.10-0.11-0.15-0.14-0.17-0.16-0.14-0.19-0.15-0.24-0.19-0.20-0.18-0.15-0.12-0.13-0.08
R&D Expense -2.77M1.59M1.98M-3.14M2.60M4.46M-4.38M4.23M3.29M3.77M3.44M3.50M2.30M1.48M1.50M646.00K1.52M1.50M2.14M4.68M4.78M4.90M6.45M6.61M8.06M8.07M6.60M8.80M7.37M7.73M8.05M9.81M7.59M6.49M3.26M2.61M2.23M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Income -4.88M-10.41M-9.90M-12.10M-15.43M-20.08M-21.48M-16.25M-13.60M-13.44M-23.44M-30.18M-38.35M-38.07M-42.43M-20.09M
Net Income -5.63M-10.91M-9.68M-12.09M-15.79M-20.03M-21.44M-16.23M-13.90M-13.29M-23.46M-30.53M-38.78M-41.07M-47.05M-30.84M
Diluted EPS -----------0.41-0.52-0.65-0.74-0.76-0.48
R&D Expense 1.07M3.55M4.53M5.69M8.43M13.11M15.32M11.72M6.47M7.47M17.98M23.82M31.74M32.13M36.57M14.29M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -6.30M6.61M9.56M10.71M29.68M26.41M15.79M4.16M9.01M48.47M29.60M41.83M21.29M28.20M17.50M19.53M
Total Equity -4.47M-1.69M-2.12M1.17M1.48M21.20M18.04M10.29M-530.00K5.17M43.87M22.47M893.00K-33.92M-61.96M-104.79M-127.92M
Cash & Equivalents 251.00K5.89M6.40M9.36M10.49M29.13M25.85M15.36M3.05M8.25M47.48M27.14M39.65M18.59M25.66M15.12M17.72M
Total Liabilities -1.78M2.21M1.64M2.49M1.70M1.36M3.78M2.97M2.11M2.87M5.41M39.21M53.48M88.44M120.56M145.73M
Current Liabilities -1.77M2.21M1.64M2.49M1.70M1.36M3.78M2.97M2.11M2.82M5.40M9.03M13.01M15.68M35.41M8.03M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -3.10M-5.68M-7.50M-7.48M---15.89M-10.18M-10.85M-20.60M-24.31M-31.06M-32.97M-41.77M-23.88M
Investing Cash Flow --15.00K64.00K---00-000000
Financing Cash Flow 8.74M6.20M10.40M8.61M--3.58M15.38M50.08M263.00K36.81M10.00M40.03M31.23M26.48M
Capital Expenditure --5.00K-5.00K-0-0-0---------
Free Cash Flow --5.68M-7.50M-7.48M-----------

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----------------
Operating Margin % ----------------
Net Margin % ----------------
ROE % 332.3%513.6%-830.5%-816.2%-74.5%-111.0%-208.3%3,063.2%-268.6%-30.3%-104.4%-3,418.5%114.3%66.3%44.9%24.1%
ROCE % -107.8%-236.7%-124.9%-147.1%-55.2%-80.2%-178.8%-1,361.9%-197.2%-29.4%-96.9%-92.0%-463.6%-304.0%236.9%-174.6%

Shareholding Pattern

Insiders
53.08%
Institutions
15.66%
Public Float
33.37%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 2.96% 2.99M $11.62M
2 Vanguard Capital Management LLC 2.15% 2.17M $8.43M
3 Geode Capital Management, LLC 1.30% 1.31M $5.09M
4 Osaic Holdings Inc. 1.19% 1.20M $4.68M
5 Marshall Wace LLP 0.82% 831.01K $3.23M
6 Wealthspire Advisors, LLC 0.72% 721.79K $2.81M
7 State Street Corporation 0.56% 567.78K $2.21M
8 Commonwealth Equity Services, LLC 0.40% 407.11K $1.58M
9 Northern Trust Corporation 0.38% 386.55K $1.50M
10 Vanguard Fiduciary Trust Co 0.36% 366.48K $1.43M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GALT

Google News Sat, 05 Sep 2026

Galectin Therapeutics Stock Price Forecast. Should You Buy GALT? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE5XMTdSclVGUEJlNERrYzZ3dU5ab0R5SUFJdDhtVnRJSkgyc2ozX3NvUTdvZ3c5bVpxRTlVTGNzbjl5UGVPRXMzWA?oc=5" target="_blank">Galectin Therapeutics Stock Price Forecast. Should You Buy GALT?</a>&…

Google News Fri, 04 Sep 2026

Galectin Therapeutics (NASDAQ:GALT) Shares Pass Above Two Hundred Day Moving Average - What's Next? - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPX0xhZ3RvclVJSi1JVUZDbG5obnlnZUNBN19xem1mcFRDWk96bGt2SExNTHgwT2tucVNzaWdiZzBKUUp5MlJvMlo5WnFzOHY5cG9sVHVPMTZ4bFFFSVMwQmhKM1gxOEJzUjRueVN3YnpJUjlSMXNxMDJfbUtkUGZYdzUwX29jT2gwaUNncF…

Google News ue, 04 Aug 2026

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. Uihlein | GALT Stock News - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxOQ1YtRjcxWmJIRkZNYlhzV1dJODVwV21oU0FUeWhNTVpRU3pUWFlBaHN4SGl3dE04cjVMMHg3QjQ2T3M5UllIdkNXMGgzenFPYTBTOUNuQlEwNHY0clRYSmVncVBpWlAxdG5LeHlWeldIVDVEVDBvcF9fNzhvQVZjVWpIVzA1ZXNacGF1UD…

Google News Wed, 24 Jun 2026

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQUjRMU2x4VE1YQlY1WjFUS3o5bjd3VVYtcEpXQ3pFWjdYbDVmNGtWOGJ4b0RJOVFVNjVCeVZod2UtUmxIVkxKcnhvNnhSdi10dmY0TlhRdGktSlJodHl5U2Mxc2NTSzB0akRjdEZJYVlDaFplRDVZckVNWVhjdDZxdGptZjBhV0pyRldiTE…

Google News ue, 23 Jun 2026

GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxNTTR1Ujc2eTd6ZEx4Z2RYdmx3S21JeGx4NmZtREsyaWxKNnJPNFl5R1pSZVdYdjNxMlo3V3gtLW5lVHJVTk4xeHlxZk05LWVrUDN6VGZOUHlJdUF1LWpkMUxqVDJRRkEzZlBxdW5aMEVpb0F5dGt2eC1HNHpRSEk2cmlPVnV6WWFiSEk1aU…

Google News ue, 26 May 2026

GALT - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBLTEN6MVRnNmFSRC1LZG83Y3hBTzFMRXBVeFBYTjZWNDA0dDdtNERsOW9UNmJ1bkV1VkxjSm8tSEswaDA1OUE?oc=5" target="_blank">GALT</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

GALT — Frequently Asked Questions

What is the current share price of Galectin Therapeutics Inc. (GALT)?

As of 2026-09-19 21:16 PDT, Galectin Therapeutics Inc. (GALT) trades at $4.14 on NasdaqCM. Its 52-week range is $2.08 to $6.51.

What is the market capitalisation of GALT?

Galectin Therapeutics Inc. (GALT) has a market capitalisation of $417.52M on NasdaqCM.

What is the P/E ratio of GALT?

GALT trades at a trailing price-to-earnings (P/E) ratio of -9.63. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -1.86.

What is the return on equity (ROE) of GALT?

GALT has a return on equity (ROE) of 24.11%.

Is GALT a good stock to buy?

This page provides a data-driven analysis of Galectin Therapeutics Inc. (GALT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space